<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439296</url>
  </required_header>
  <id_info>
    <org_study_id>T2005-001</org_study_id>
    <nct_id>NCT00439296</nct_id>
  </id_info>
  <brief_title>ABT-751 With Chemotherapy for Relapsed Pediatric ALL</brief_title>
  <official_title>A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutic Advances in Childhood Leukemia Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Therapeutic Advances in Childhood Leukemia Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott&#xD;
      Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic&#xD;
      leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done&#xD;
      to find the highest dose of ABT-751 that can be given safely in combination with other&#xD;
      chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects.&#xD;
      After a safe dose for ABT-751 given with chemotherapy has been found, the study will add&#xD;
      additional patients to find out if ABT-751 (given at the maximal safe dose) when given with&#xD;
      additional chemotherapy is an effective therapy for the treatment of children with relapsed&#xD;
      ALL. It is expected that approximately 15-35 children and young adults will take part in this&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive the 2 courses of chemotherapy unless medical complications prevent&#xD;
      the administration of some of the drugs. Treatment for the first 2 courses of therapy will&#xD;
      last about 2 months.&#xD;
&#xD;
      Treatment on this study will consist of a combination of 8 anti-cancer medications. The 8&#xD;
      anticancer medicines are ABT-751, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine&#xD;
      (Ara-C), methotrexate (MTX), cyclophosphamide, and 6-thioguanine. All the drugs except&#xD;
      ABT-751 are well known anti-cancer drugs and have been used extensively in the treatment of&#xD;
      cancer.&#xD;
&#xD;
      During the Phase I portion of this study, when you enroll, you will be given an assigned dose&#xD;
      of ABT-751. The dose of ABT-751 will be based on doses given in previous studies done with&#xD;
      adults and children. At each dose level of ABT-751, between 3 and 6 children will receive&#xD;
      ABT-751 in combination with chemotherapy. If the side effects are not too severe, the next&#xD;
      group of children will receive a higher dose. The dose will continue to be increased until we&#xD;
      find the dose that causes serious side effects. Your dose of ABT-751 will not be increased.&#xD;
      If you have bad side effects, your dose may be decreased.&#xD;
&#xD;
      The dose used during the Phase 2 part of this study will be determined by the outcome of the&#xD;
      Phase I study. The highest dose used in Phase I that was tolerated without serious side&#xD;
      effects will be the one used in Phase 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped due to poor accrual and lack of funding.&#xD;
  </why_stopped>
  <start_date>May 22, 2006</start_date>
  <completion_date type="Actual">September 23, 2009</completion_date>
  <primary_completion_date type="Actual">May 19, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients That Experienced Dose Limiting Toxicity From ABT-751</measure>
    <time_frame>Each dose level is evaluated</time_frame>
    <description>ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course.&#xD;
DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).&#xD;
Grade 3 or 4 Ileus&#xD;
Grade 3 or 4 Constipation&#xD;
Grade 3 or 4 Gastrointestinal obstruction, any location&#xD;
Grade 3 or 4 Sensory Neuropathy&#xD;
Grade 3 or 4 Motor Neuropathy&#xD;
Grade 3 or 4 Neuropathic pain lasting longer than 24 hours despite medical intervention&#xD;
Grade 3 or 4 Hypoxia in the absence of anemia or infection&#xD;
Grade 4 Alanine aminotransferase (ALT) which does not return to</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients That Achieved Complete Response to ABT-751</measure>
    <time_frame>Day 29 of Course 1</time_frame>
    <description>Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) &gt; 750/μL and Platelet count &gt; 75,000 μL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Occurrence of Toxic Death</measure>
    <time_frame>From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21.</time_frame>
    <description>The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Recurrent Pediatric ALL</condition>
  <condition>Relapsed Pediatric ALL</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Pediatric ALL</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 80 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 100 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 125 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 150 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 175 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 65 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Dose of ABT-751 is 50 mg/m2/day&#xD;
Tx Course 1:&#xD;
• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate&#xD;
Tx Course 2:&#xD;
• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751&#xD;
Tx Courses 3-12 (maintenance courses):&#xD;
• ABT-751, IT Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-751</intervention_name>
    <description>Treatment Course 1:&#xD;
Oral capsule to be given daily for 21 days at assigned dose.&#xD;
Treatment Course 2:&#xD;
ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.&#xD;
Treatment Course 3:&#xD;
ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Antineoplastics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>In Treatment Course 1 only:&#xD;
10 mg/m2/day divided BID.&#xD;
Take dexamethasone by mouth days 1-14.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexasone</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asparaginase</intervention_name>
    <description>In Treatment Course 1:&#xD;
2500 IU's/m2/day.&#xD;
Intramuscular injection (IM) on days 4, 11 and 18.&#xD;
In Treatment Course 2:&#xD;
2500 IU's/m2/day.&#xD;
Intramuscular injection (IM) on day 15.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-asparaginase</other_name>
    <other_name>Erwinia L-asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>In Treatment Course 1 only:&#xD;
• 60 mg/m2/day IV over 15 minutes on day 1.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given Intrathecally on day 1 of course 1 at the dose defined by age below.&#xD;
30 mg for patients age 1-1.99&#xD;
50 mg for patients age 2-2.99&#xD;
70 mg for patients &gt;3 years of age&#xD;
Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.&#xD;
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Arabinosylcytosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>In Treatment Course 1:&#xD;
• Given Intrathecally on day 15 at the dose defined by age below.&#xD;
8 mg for patients age 1-1.99&#xD;
10 mg for patients age 2-2.99&#xD;
12 mg for patients 3-8.99 years of age&#xD;
15 mg for patients &gt;9 years of age&#xD;
In Treatment Course 2:&#xD;
• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.&#xD;
8 mg for patients age 1-1.99&#xD;
10 mg for patients age 2-2.99&#xD;
12 mg for patients 3-8.99 years of age&#xD;
15 mg for patients &gt;9 years of age&#xD;
In Treatment Course 3:&#xD;
Intrathecally on day 1 at the age-defined dose</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Otrexup</other_name>
    <other_name>Rasuvo</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Trexall</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Methotrexate Sodium</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-thioguanine</intervention_name>
    <description>Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Thioguanine Tabloid</other_name>
    <other_name>6-TG</other_name>
    <other_name>2-Amino-6-Mercaptopurine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age Patients must be &lt; 21 years of age when enrolled onto this study. T2005-001&#xD;
             Protocol version 6/27/2007 17&#xD;
&#xD;
          2. Diagnosis&#xD;
&#xD;
             Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts &gt;25%)&#xD;
             without clinical evidence of testicular disease or laboratory evidence of CNS disease&#xD;
             defined as CSF WBC &gt; 5 cells/microliter and blasts. (See Appendix I for method of&#xD;
             evaluating traumatic lumbar punctures.) Patients in early first relapse (defined as a&#xD;
             patient who relapses less than 36 months from their initial remission [CR1]) are&#xD;
             eligible for the phase I portion of the trial.&#xD;
&#xD;
          3. Performance Level Karnofsky &gt; 60% for patients &gt; 10 years of age and Lansky &gt; 60% for&#xD;
             patients &lt; 10 years of age.&#xD;
&#xD;
          4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all&#xD;
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
&#xD;
               1. Prior anthracycline exposure: Patients must have less than 300mg/m2 lifetime&#xD;
                  exposure of anthracycline chemotherapy. (See Appendix III for calculation&#xD;
                  criteria)&#xD;
&#xD;
               2. Stem Cell Transplant (SCT): Patients are eligible 6 months after allogeneic stem&#xD;
                  cell transplant as long as patients are not actively being treated for&#xD;
                  graft-versus-host-disease (GvHD).&#xD;
&#xD;
               3. During the phase I portion of the trial, there is no limit on the number of prior&#xD;
                  treatment regimens.&#xD;
&#xD;
               4. During the phase II portion of the trial, patients must have had two or more&#xD;
                  prior therapeutic attempts defined as:&#xD;
&#xD;
                    -  Persistent initial disease after two induction attempts, or&#xD;
&#xD;
                    -  Relapse after one-reinduction attempt (2nd relapse), or&#xD;
&#xD;
                    -  Persistent disease after first relapse and initial re-induction attempt&#xD;
                       (Patients in any first relapse are not eligible for the phase II portion of&#xD;
                       the study)&#xD;
&#xD;
               5. During the phase II portion of the trial, patients must have no more than 3 prior&#xD;
                  therapeutic attempts and it must be at least 6 months since the last treatment&#xD;
                  with a &quot;VPLD&quot; induction/re-induction regimen.&#xD;
&#xD;
          5. Reproductive Function&#xD;
&#xD;
               1. Female patients of childbearing potential must have a negative urine or serum&#xD;
                  pregnancy test confirmed prior to enrollment and within 48 hours of starting&#xD;
                  therapy.&#xD;
&#xD;
               2. Female patients with infants must agree not to breastfeed their infants while on&#xD;
                  this study.&#xD;
&#xD;
               3. Male and female patients of child-bearing potential must agree to use an&#xD;
                  effective method of contraception approved by the investigator during the study&#xD;
                  and for 3 months following completion of therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Drug Allergies&#xD;
&#xD;
             Patients will be excluded if they have allergies to the following drugs:&#xD;
&#xD;
               -  Asparaginase products&#xD;
&#xD;
               -  Sulfa containing medications&#xD;
&#xD;
          2. Renal Function Patients will be excluded if their serum creatinine is &gt; the upper&#xD;
             limit of normal (ULN) for age at the institution's laboratory.&#xD;
&#xD;
          3. Liver/Pancreatic Function&#xD;
&#xD;
               1. Direct bilirubin &gt; 1.5x the institutional ULN for age. A total bilirubin result&#xD;
                  that is less than 1.5 times the institutional ULN for age may be used for&#xD;
                  eligibility if a direct bilirubin result is not available.&#xD;
&#xD;
               2. SGPT (ALT) &gt; 4 x institutional ULN&#xD;
&#xD;
               3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0&#xD;
&#xD;
               4. Amylase or Lipase &gt; 2 x institutional ULN&#xD;
&#xD;
          4. Cardiac Function Patients will be excluded if their shortening fraction by&#xD;
             echocardiogram is less than 30%.&#xD;
&#xD;
          5. Infection Patients will be excluded if they have an active, uncontrolled infection.&#xD;
&#xD;
               1. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0&#xD;
                  criteria.&#xD;
&#xD;
               2. Patients with grade 2 or greater Ileus (neuroconstipation) per CTC 3.0 criteria.&#xD;
&#xD;
               3. Patients currently being treated with coumadin.&#xD;
&#xD;
               4. Patients currently being treated with colchicines.&#xD;
&#xD;
               5. Patients planning on receiving other investigational agents while on this study.&#xD;
                  (An investigational agent is defined as any drug not currently approved for use&#xD;
                  in humans.)&#xD;
&#xD;
               6. Patients planning on receiving other anti-cancer therapies while on this study.&#xD;
&#xD;
               7. Patients who, in the opinion of the investigator, may not be able to comply with&#xD;
                  the safety monitoring requirements of the study.&#xD;
&#xD;
               8. Patients who, based on BSA and current dose level, require a daily dose of&#xD;
                  ABT-751 that is less than 25mg per day.&#xD;
&#xD;
               9. Patients who have started protocol therapy prior to enrollment. Patient may still&#xD;
                  enroll if IT Ara-C or IT MTX were given within 48 hours of study enrollment as&#xD;
                  part of the diagnostic lumbar procedure. These patients will not participate in&#xD;
                  the CSF PK portion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S Gaynon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Childrens Hospital Los Angeles, Therapeutic Advances in Childhood Leukemia Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tacl.us</url>
    <description>Therapeutic Advances in Childhood Leukemia &amp; Lymphoma Consortium web site</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Recurrence</keyword>
  <keyword>ABT-751</keyword>
  <keyword>Therapeutic Advances in Childhood Leukemia</keyword>
  <keyword>Investigational</keyword>
  <keyword>Childhood</keyword>
  <keyword>ALL</keyword>
  <keyword>Relapsed ALL</keyword>
  <keyword>Refractory ALL</keyword>
  <keyword>Relapsed pediatric ALL</keyword>
  <keyword>Refractory pediatric ALL</keyword>
  <keyword>TACL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 0</title>
          <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Course 1</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Course 2</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1</title>
          <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 0</title>
          <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Experienced Dose Limiting Toxicity From ABT-751</title>
        <description>ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course.&#xD;
DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).&#xD;
Grade 3 or 4 Ileus&#xD;
Grade 3 or 4 Constipation&#xD;
Grade 3 or 4 Gastrointestinal obstruction, any location&#xD;
Grade 3 or 4 Sensory Neuropathy&#xD;
Grade 3 or 4 Motor Neuropathy&#xD;
Grade 3 or 4 Neuropathic pain lasting longer than 24 hours despite medical intervention&#xD;
Grade 3 or 4 Hypoxia in the absence of anemia or infection&#xD;
Grade 4 Alanine aminotransferase (ALT) which does not return to</description>
        <time_frame>Each dose level is evaluated</time_frame>
        <population>Number of participants that completed at least 1 course of treatment and are evaluable for toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 0</title>
            <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Experienced Dose Limiting Toxicity From ABT-751</title>
          <description>ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course.&#xD;
DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).&#xD;
Grade 3 or 4 Ileus&#xD;
Grade 3 or 4 Constipation&#xD;
Grade 3 or 4 Gastrointestinal obstruction, any location&#xD;
Grade 3 or 4 Sensory Neuropathy&#xD;
Grade 3 or 4 Motor Neuropathy&#xD;
Grade 3 or 4 Neuropathic pain lasting longer than 24 hours despite medical intervention&#xD;
Grade 3 or 4 Hypoxia in the absence of anemia or infection&#xD;
Grade 4 Alanine aminotransferase (ALT) which does not return to</description>
          <population>Number of participants that completed at least 1 course of treatment and are evaluable for toxicities.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of patients with DLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of patients without DLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Achieved Complete Response to ABT-751</title>
        <description>Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) &gt; 750/μL and Platelet count &gt; 75,000 μL.</description>
        <time_frame>Day 29 of Course 1</time_frame>
        <population>Number of patients that completed at least 1 course of treatment and was evaluable for response assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 0</title>
            <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Achieved Complete Response to ABT-751</title>
          <description>Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) &gt; 750/μL and Platelet count &gt; 75,000 μL.</description>
          <population>Number of patients that completed at least 1 course of treatment and was evaluable for response assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of patients not achieving complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of patients who achieved complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Occurrence of Toxic Death</title>
        <description>The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment.</description>
        <time_frame>From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21.</time_frame>
        <population>Number of patients that completed at least 1 course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 0</title>
            <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Occurrence of Toxic Death</title>
          <description>The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment.</description>
          <population>Number of patients that completed at least 1 course of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of patients that experienced toxic death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of patients that did not experience toxic death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events will be collected and reported on the electronic case report forms beginning with the first dose of investigational product until 30 days following the last dose of ABT-751, whether elicited or spontaneously reported by the patient, up to day 51 days (30 days after day 21, last day of the protocol therapy).</time_frame>
      <desc>The definition of adverse event (AE) and serious adverse event (SAE) do not differ from the clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1</title>
          <description>Starting dose for study is 80 mg/m2/day of ABT-751</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 0</title>
          <description>De-escalation dose due to DLTs: 65 mg/m2/day of ABT-751</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/ Gr 3/4 ANC, Blood</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr 3/4 ANC, Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr 3/4 ANC, Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow-Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Colitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastro-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema - limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/Pancreas-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr 3/4 ANC, Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr 3/4 ANC, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab-Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuralgia NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to lack of accrual. Data were not analyzed for outcome variables.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peggy Romano, BA, CCRP</name_or_title>
      <organization>Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) / Children's Hospital Los Angeles</organization>
      <phone>323-361-5505</phone>
      <email>promano@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

